« Return to News | Clinical Intelligence

Conatus Pharmaceuticals begins phase II trial of CTS-1027 for hepatitis C

Tuesday, March 1, 2011 08:03 AM

Conatus Pharmaceuticals has treated its first patient in a multi-center phase IIb clinical trial evaluating CTS-1027 in combination with Peginterferon Alfa-2a (PegasysR) and ribavirin (CopegusR) in a treatment experienced, hepatitis C (HCV) null responder patient population.

CTS-1027 inhibits the activity of key members of a class of protease enzymes, the matrix metalloproteinases or MMPs. CTS-1027 has reduced and/or blocked HCV infection in in vitro preclinical models. It has potential to amplify the effectiveness of existing therapies in HCV-infected patients. CTS-1027 has well established anti-inflammatory and anti-fibrotic effects shown in models of acute hepatitis and liver fibrosis.

This clinical trial is a placebo-controlled, multicenter, double-blind, randomized trial. Dosing will last for up to 48 weeks. The company expects to enroll approximately 260 patients and will be conducted at up to 50 medical centers in the U.S.

 

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.